BLU-945 is one of the fastest advancing fourth-generation EGFR inhibitors in research, and BLU-945 alone or in combination with oxitinib showed early signals of clinical activity and was well tolerated in a large number of pre-treated EGFR-mutated non-small cell lung cancer patients[21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.